Exelixis Inc EXEL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update
Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm
FDA Extends Review of Exelixis' Zanzalintinib in Colorectal Cancer
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories
Trading Information
- Previous Close Price
- $70.58
- Day Range
- $69.66–70.96
- 52-Week Range
- $39.71–73.69
- Bid/Ask
- $70.00 / $70.72
- Shares Outstanding
- 244.01M
- Market Cap
- $17.25B
- Volume/Avg
- 2M / 2M
Key Statistics
- Price/Earnings (Normalized)
- 19.28
- Price/Sales
- 7.48
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 7.32%
Company Profile
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 1,077
- Website
- https://www.exelixis.com
Valuation
Metric | EXEL |
|---|---|
Price/Earnings (Normalized) | 19.28 |
Price/Book Value | 9.42 |
Price/Sales | 7.48 |
Price/Cash Flow | 15.80 |
Price/Earnings
EXEL
Financial Strength
Metric | EXEL |
|---|---|
Quick Ratio | 2.96 |
Current Ratio | 3.21 |
Interest Coverage | — |
Quick Ratio
EXEL
Profitability
Metric | EXEL |
|---|---|
Return on Assets (Normalized) | 36.53% |
Return on Equity (Normalized) | 48.79% |
Return on Invested Capital (Normalized) | 42.57% |
Return on Assets
EXEL
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|S&r!?h | LOCK|&zQ<F | $139B | |||
| Moderna Inc MRNA | LOCK|%gMy&&L | LOCK|%DF | $101B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|MP%^Rl | LOCK|<#wV | $95B | |||
| argenx SE ADR ARGX | LOCK|^V%?N& | LOCK|>#c | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|xc>&Xmy | LOCK|k& | $49B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|MClQPb^$ | LOCK|p<%b | $31B | |||
| Incyte Corp INCY | LOCK|%m>S^V | LOCK|k@M | $25B | |||
| BioNTech SE ADR BNTX | LOCK|%tX$dH< | LOCK|!!@ | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|Z!M?>?@ | LOCK|^r!qy | $20B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|>B@h#? | LOCK|FZn | $16B |
United States